Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/25/1000mg in Healthy Volunteers

NCT ID: NCT07304687

Last Updated: 2025-12-26

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 31 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-10-24
• Study Completion Date: 2025-11-22

Brief Summary

This study is a randomized, open-label, single dose, crossover study to evaluate the pharmacokinetics and safety of CKD-383 in healthy volunteers

Detailed Description

To 30 healthy subjects, following treatments, are administered dosing in each period and wash-out period is 7 days. Pharmacokinetic blood samples are collected up to 48hrs. The pharmacokinetic characteristics and safety are assessed.

Conditions

Type 2 Diabetes

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

RT

Period 1: A single oral dose of 3 tablets under fasting condition(CKD-501, D745, D150), Period 2: A single oral dose of 1 tablet under fasting condition(CKD-383)

Group Type: EXPERIMENTAL

CKD-383 0.5/25/1000mg

Intervention Type: DRUG

QD, PO

CKD-501, D745, D150

Intervention Type: DRUG

QD, PO

TR

Period 1: A single oral dose of 1 tablet under fasting condition(CKD-383), Period 2: A single oral dose of 3 tablets under fasting condition(CKD-501, D745, D150)

Group Type: EXPERIMENTAL

CKD-383 0.5/25/1000mg

Intervention Type: DRUG

QD, PO

CKD-501, D745, D150

Intervention Type: DRUG

QD, PO

Interventions

CKD-383 0.5/25/1000mg

QD, PO

Intervention Type: DRUG

CKD-501, D745, D150

QD, PO

Intervention Type: DRUG

Other Intervention Names

Test; Reference

Eligibility Criteria

Inclusion Criteria

1. Individuals who is 19 years of age or older at the time of the screening visit

2. Individuals who had 18.0 kg/m2 ≤ Body Mass Index(BMI) < 30.0 kg/m2 and total body weight ≥ 50 kg BMI = Weight(kg)/ Height(m)2

3. Individuals who do not have clinically meaningful congenital or chronic diseases and who do not have medical examination results (such as electroencephalogram, electrocardiogram, chest and gastroscopy or gastrointestinal radiography, if necessary) during screening visits

4. Individuals determined by investigators to be suitable for testing as a result of diagnostic tests and electrocardiogram tests, such as hematology tests, blood chemistry tests, serum tests, urine tests, etc

5. Individuals who agreed proper contraception during the study and did consent to not donation of sperm or eggs 7 days after the last dose of study drug

6. Individuals who signed an informed consent form after being fully informed of the study prior to participation, including the objective and content

Exclusion Criteria

1. Individuals who has a history of gastrointestinal surgery (excluding simple appendectomy or hernia surgery) that may affect the absorption of drugs or has a gastrointestinal disease

2. Individuals who has used a drug metabolase-inducing and inhibiting drug such as barbitals within one month prior to the first dosing date or a drug that may interfere with this test within 10 days prior to the first administration of investigational product

3. Individuals who had been administered investigational product from other clinical study or bioequivalence study within the 6 months prior to the first administration of investigational product

4. Individuals who donated whole blood within the 8 weeks, or blood components within 2 weeks or had a blood transfusion within 4 weeks prior to the first administration of investigational product

5. Individuals who meets the following conditions within one month prior to the first administration of investigational product

• Man: average alcohol consumption > 21 cups/weeks
• Woman: average alcohol consumption > 14 cups/weeks
• Smoking > 20 cigarettes

6. Patients with the following conditions

• Patients with hypersensitivity to investigational product or biguanide drugs
• Patients with acute or chronic metabolic acidosis including type 1 diabetes, lactic acidosis, comatose or not diabetic ketoacidosis, and patients with a history of ketoacidosis
• Acute conditions that can affect renal functions such as moderate (stage3b) and severe renal impairment (glomerular filtration rate <45ml/min/1.73m2), dehydration, severe infection, cardiovascular despondency (shock), acute myocardial infarction, sepsis, etc
• Patients with acute and unstable heart failure or severe heart failure or a history of heart failure
• Patients undergoing tests for intravenous administration of radioiodine contrast agents (e.g., intravenous urinary tract, intravenous cholangiography, angiography, computed tomography with contrast agents, etc.)
• Diabetic coma and pre-coma
• Patients with severe infections or severe traumatic systemic disorders
• Patients scheduled for surgery
• Patients with malnutrition, starvation, weakness, pituitary dysfunction or adrenal insufficiency
• Acute or chronic patients who can cause liver dysfunction, respiratory failure, and tissue hypoxia
• Patients with genetic problems such as galactose intolerance, Lap lactase deficiency, or glucose-galactose malabsorption

7. Individuals with a clinically significant history of mental illness

8. Those who are deemed insufficient to participate in this clinical study by investigators

9. Pregnant women, women who may be pregnant, nursing women

• Minimum Eligible Age: 19 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Chong Kun Dang Pharmaceutical

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

H Plus Yangji Hospital

Seoul, , South Korea

Countries

South Korea

Other Identifiers

A101_09BE2507

Identifier Type: -

Identifier Source: org_study_id